Comparative effects of telmisartan and lisinopril on cognitive function in metabolic syndrome patients

Gore, Pradip N.; Badar, Vandana; Hardas, Mrunalini M.; Bansode, Varsha J.; Navale, Sanjay B

doi:10.4103/2348-8093.143495

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But there was a significant increase in remote and recent memory scores in the Telmisartan group compared to baseline. Our results were consistent with the previous studies [20,30,31]. Kavitha et al [20] compared Telmisartan with Olmesartan in 101 hypertensive patients.…”

Section: ) Secondary Outcomessupporting

confidence: 94%

“…We observed an improving trend in these scores more in Telmisartan group, though they were not statistically significant. Our results are consistent with the previous studies [20,30,31]. A significant improvement was observed in Cilnidipine group when compared to Telmisartan group in six letter cancellation test and Digit Letter Substitution Test.…”

Section: ) Secondary Outcomessupporting

confidence: 93%

“…They concluded that losartan group had a significant improvement in both recent and remote memory tests at the end of the study and Losartan showed significant improvement in both memory tests compared to Atenolol. Another study [31] proved that Telmisartan was associated with an improvement in cognitive functions compared to Lisinopril in metabolic syndrome patients after 12 weeks. A meta-analysis [32] showed that ARBs can enhance cognitive functions in the elderly, especially episodic memory.…”

Section: ) Secondary Outcomesmentioning

confidence: 97%

See 2 more Smart Citations

The effect of Telmisartan versus Cilnidipine on memory and psychomotor functions in patients with essential hypertension - An open label, randomized, parallel comparative study

Bisoi

Aruna

Authorea

View full text Add to dashboard Cite

Introduction: Hypertension is a global public health issue. Data on the effect of Anti-hypertensive drugs on dementia, Alzheimer's disease, cognitive impairment is limited and inconclusive. Material and Methods: It was a Prospective, randomized, open label, comparative study. Total 60 hypertensive Patients were randomized to receive either Telmisartan or Cilnidipine. Memory functions were evaluated with PGI Memory Scale, while psychomotor functions were evaluated with Six Letter Cancellation test (SLCT) and Digit Letter Substitution test (DLST) and card sorting test (CST). Student t-test was used to compare the means of test scores between and within the groups. Statistical significance was considered at P<0.05. Results: An improvement was observed in scores of memory in both the groups which was not significant. A significant improvement (p < 0.05) was shown in 3 of 10 subtests of memory in Telmisartan group compared to Cilnidipine. Both the drugs showed significant improvement in psychomotor function tests (P<0.05). SLCT score was 40.33 ± 1.58 in Cilnidipine group and 38.80 ± 1.56 (CI 37.2 -40.4) in Telmisartan group. Cilnidipine showed significant improvement in SLCT and DLST scores compared to Telmisartan. Both the study drugs decreased BP significantly (P < 0.01). Conclusion: Both Telmisartan and Cilnidipine showed no change in memory and significant improvement in psychomotor functions in newly diagnosed Stage -I essential hypertension patients. But Telmisartan showed more improving trends in memory than Cilnidipine. Cilnidipine significantly improved psychomotor functions compared to Telmisartan. Further randomized controlled studies are needed to establish these effects.The effect of Telmisartan versus Cilnidipine on memory and psychomotor functions in patients with essential hypertension -An open label, Randomized, parallel, comparative study Summary Introduction: Hypertension is a global public health issue. Data on the effect of Anti-hypertensive drugs on dementia, Alzheimer's disease, cognitive impairment is limited and inconclusive.Material and Methods: It was a Prospective, randomized, open label, comparative study. Total 60 hypertensive Patients were randomized to receive either Telmisartan or Cilnidipine. Memory functions were evaluated with PGI Memory Scale, while psychomotor functions were evaluated with Six Letter Cancellation test (SLCT) and Digit Letter Substitution test (DLST) and card sorting test (CST). Student t-test was used to compare the means of test scores between and within the groups. Statistical significance was considered at P<0.05. Results: An improvement was observed in scores of memory in both the groups which was not significant. A significant improvement (p < 0.05) was shown in 3 of 10 subtests of memory in Telmisartan group compared to Cilnidipine. Both the drugs showed significant improvement in psychomotor function tests (P<0.05). SLCT score was 40.33 ± 1.58 in Cilnidipine group and 38.80 ± 1.56 ) in Telmisartan group. Cilnidipine showed significant improvement in SLCT ...

show abstract

Section: ) Secondary Outcomessupporting

confidence: 94%

Section: ) Secondary Outcomessupporting

confidence: 93%

Section: ) Secondary Outcomesmentioning

confidence: 97%

See 1 more Smart Citation

The effect of Telmisartan versus Cilnidipine on memory and psychomotor functions in patients with essential hypertension - An open label, randomized, parallel comparative study

Bisoi

Aruna

Authorea

View full text Add to dashboard Cite

show abstract

“…In some experimental animal models of AD, telmisartan exhibited significant ameliorative effects on the impaired spatial memory and inflammatory response [16][17][18][19]. Clinical investigation demonstrated that telmisartan improves cognitive function in patients with metabolic syndrome and elderly hypertensive patients with AD, type 3 diabetes [20,21]. Our previous studies showed that telmisartan at nonhypotensive dose reverses memory impairment in streptozotocin (STZ) -induced diabetic mice [22].…”

Section: Introductionmentioning

confidence: 99%

Telmisartan Improves Memory Impairment in a Mouse Model of Type 2 Diabetes

Dg¹,

Rr²,

Jl³

et al. 2016

Clin Exp Pharmacol

View full text Add to dashboard Cite

Telmisartan, an angiotensin II type 1-receptor blocker (ARB), has been reported to exert beneficial effects on the central nervous system (CNS) in streptozotocin (STZ)-induced diabetic mice. However, the effect of telmisartan on cognitive impairment associated with type 2 diabetes is not well known. Here, we investigated the effects of telmisartan on memory impairment in a mouse model with defects in insulin sensitivity and secretion, namely highfat diet (HFD) /STZ-induced diabetic mice. Our data showed that STZ / HFD diabetic mice, characterized by hyperglycemia and hypoinsulinemia, performed poorly on Morris water maze (MWM) test. Such learning and memory impairment was accompanied by increased β-amyloid peptide 42 (Aβ42), amyloid precursor protein (APP), β-site amyloid precursor protein cleaving enzyme (BACE1), the receptor for advanced glycation end products (RAGE) and nuclear factor-κB (NF-κB) signaling in brain. Treatment with telmisartan significantly improved learning and memory in the diabetic mice and decreased Aβ42, APP, BACE1 RAGE and NF-κB signaling in the brain without affecting hyperglycemia and hypoinsulinemia. It is concluded that telmisartan may be considered as a potential pharmacological agent for the management of cognitive dysfunction in type 2 diabetes.

show abstract

Comparative effects of telmisartan and lisinopril on cognitive function in metabolic syndrome patients

Cited by 2 publications

References 0 publications

The effect of Telmisartan versus Cilnidipine on memory and psychomotor functions in patients with essential hypertension - An open label, randomized, parallel comparative study

The effect of Telmisartan versus Cilnidipine on memory and psychomotor functions in patients with essential hypertension - An open label, randomized, parallel comparative study

Telmisartan Improves Memory Impairment in a Mouse Model of Type 2 Diabetes

Contact Info

Product

Resources

About